SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $83,929.00 in Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 4,937 shares of SI-BONE stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the sale, the chief financial officer now owns 265,356 shares of the company’s stock, valued at $4,511,052. This trade represents a 1.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

SI-BONE Stock Performance

Shares of NASDAQ:SIBN opened at $18.51 on Friday. The company’s 50 day simple moving average is $14.53 and its 200 day simple moving average is $14.82. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $19.16. The stock has a market capitalization of $787.21 million, a price-to-earnings ratio of -20.12 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. As a group, research analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on SIBN shares. Needham & Company LLC reiterated a “buy” rating and issued a $24.00 price target on shares of SI-BONE in a research report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial increased their target price on SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of SI-BONE by 4.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company’s stock valued at $328,000 after purchasing an additional 988 shares during the last quarter. Invesco Ltd. grew its stake in shares of SI-BONE by 8.9% during the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company’s stock worth $241,000 after buying an additional 1,413 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of SI-BONE by 3.0% during the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock worth $808,000 after buying an additional 1,683 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in shares of SI-BONE during the first quarter worth $34,000. Finally, Barclays PLC lifted its stake in shares of SI-BONE by 2.7% in the 4th quarter. Barclays PLC now owns 99,212 shares of the company’s stock valued at $1,391,000 after acquiring an additional 2,589 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.